



ASX Announcement

12th April 2013

Sirtex completes SIRFLOX patient recruitment

Sydney, Australia, 12th April 2013 – Sirtex Medical Limited (ASX: SRX) is pleased to announce the completion of patient recruitment onto the company’s flagship SIRFLOX randomised controlled trial of SIR-Spheres[®] microspheres in patients with metastatic colorectal cancer (mCRC).

Mr Gilman Wong, Sirtex’s Chief Executive Officer said “Sirtex is committed to delivering the Level 1 clinical evidence from large randomised controlled trials confirming the effectiveness of SIR-Spheres microspheres. We believe that if the results from the SIRFLOX study are positive, SIR-Spheres microspheres will be elevated to a first-line therapy for patients with colorectal liver metastases, providing important clinical benefits to patients and leading to a step-change in Sirtex’s business.

“The completion of patient recruitment onto the SIRFLOX study has required the participation of more than 100 leading hospitals globally and considerable resources over six years.”

The SIRFLOX study which is expected to deliver its primary results in late 2014 is the largest randomised controlled trial ever undertaken in the field of interventional oncology. The SIRFLOX study aims to evaluate whether a first-line treatment strategy of using the current standard-of-care chemotherapy plus SIR-Spheres microspheres is more effective than chemotherapy alone, in patients with inoperable liver metastases from primary colorectal cancer (bowel cancer).

Professor Peter Gibbs, Consultant Medical Oncologist at The Royal Melbourne Hospital and Global Principal Investigator on the SIRFLOX study said “Over the past decade we have seen mostly incremental improvements in the treatment options for patients with advanced colorectal cancer. Clinicians and their patients need new options and the results of the SIRFLOX study will be eagerly anticipated.”

Mr Wong said “Sirtex has been marketing SIR-Spheres microspheres for over a decade and while we have an established position as a last-line salvage therapy, many more patients may benefit from selective internal radiation therapy (SIRT) with SIR-Spheres microspheres if it is elevated to a first-line treatment option. We are very pleased to have completed patient recruitment and we wish to thank the patients, physician investigators and research staff involved in SIRFLOX for their participation in this landmark clinical study.

For further information please contact:

Gilman Wong
CEO Sirtex Medical Limited
(02) 9964 8400

Tim Allerton or Andrew Geddes
City PR
(02) 9267 4511